Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.

Kimura Y, Takano K, Satoh K, Aida K, Kobayashi T, Ozaki Y.

Clin Appl Thromb Hemost. 2014 Sep;20(6):629-36. doi: 10.1177/1076029613488934. Epub 2013 May 14.

PMID:
23677911
2.

Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.

Kobzar G, Mardla V, Samel N.

Platelets. 2011;22(5):338-44. doi: 10.3109/09537104.2010.535931. Epub 2011 May 11.

PMID:
21557683
3.

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes.

Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davì G, Patrono C.

J Thromb Haemost. 2012 Jul;10(7):1220-30. doi: 10.1111/j.1538-7836.2012.04723.x.

4.

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.

Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS.

J Thromb Haemost. 2007 Mar;5(3):490-6.

5.

Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.

Guthikonda S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, Dong JF, Lev EI, Kleiman NS.

Thromb Haemost. 2008 Jul;100(1):83-9. doi: 10.1160/TH07-10-0590.

PMID:
18612542
6.

Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.

Smith JP, Haddad EV, Taylor MB, Oram D, Blakemore D, Chen Q, Boutaud O, Oates JA.

Hypertension. 2012 Mar;59(3):719-25. doi: 10.1161/HYPERTENSIONAHA.111.181404. Epub 2012 Feb 6.

7.

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ.

J Thromb Thrombolysis. 2014;37(2):131-8. doi: 10.1007/s11239-013-0979-8.

PMID:
23943337
8.

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control.

Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J.

Thromb Res. 2004;113(2):101-13.

PMID:
15115665
9.
10.

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.

Circulation. 2007 Jun 26;115(25):3156-64. Epub 2007 Jun 11.

11.

Variable platelet response to aspirin in patients with ischemic stroke.

Hohlfeld T, Weber AA, Junghans U, Schumacher M, Boucher M, Schrör K, Siebler M.

Cerebrovasc Dis. 2007;24(1):43-50. Epub 2007 May 22.

PMID:
17519543
12.

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C.

J Am Coll Cardiol. 2009 Feb 24;53(8):667-77. doi: 10.1016/j.jacc.2008.10.047.

13.

Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.

Pettinella C, Romano M, Stuppia L, Santilli F, Liani R, Davì G.

Thromb Haemost. 2009 Apr;101(4):687-90.

PMID:
19350112
14.

Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies.

Crescente M, Jessen G, Momi S, Höltje HD, Gresele P, Cerletti C, de Gaetano G.

Thromb Haemost. 2009 Aug;102(2):336-46. doi: 10.1160/TH09-01-0057.

PMID:
19652885
15.

Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control.

Mylotte D, Kavanagh GF, Peace AJ, Tedesco AF, Carmody D, O'Reilly M, Foley DP, Thompson CJ, Agha A, Smith D, Kenny D.

Platelets. 2012;23(6):439-46. doi: 10.3109/09537104.2011.634932. Epub 2011 Dec 13.

PMID:
22150374
16.

New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.

Kovács EG, Katona E, Bereczky Z, Homoródi N, Balogh L, Tóth E, Péterfy H, Kiss RG, Edes I, Muszbek L.

Thromb Res. 2013 Apr;131(4):320-4. doi: 10.1016/j.thromres.2013.01.033. Epub 2013 Feb 17.

PMID:
23422285
17.

Aspirin twice a day keeps new COX-1 at bay.

Lordkipanidzé M, Harrison P.

J Thromb Haemost. 2012 Jul;10(7):1217-9. doi: 10.1111/j.1538-7836.2012.04764.x. No abstract available.

18.

Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.

Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM.

Circulation. 2007 May 15;115(19):2490-6. Epub 2007 Apr 30.

19.

Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.

Moscardó A, Santos MT, Fuset MP, Ruano M, Vallés J.

Thromb Haemost. 2011 Apr;105(4):663-9. doi: 10.1160/TH10-08-0550. Epub 2011 Feb 8.

PMID:
21301784
20.

Supplemental Content

Support Center